Renal Cancer - Results from #1920

Optimizing the management of patients with small renal masses in a Canadian context: A Markov decision-analysis model. September 2, 2021

Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. September 2, 2021

CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. September 1, 2021

Robotic surgery for cT2 kidney cancer: analysis of the National Cancer Database. August 31, 2021

Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. August 31, 2021

Systemic Inflammation Response Index is an Independent Prognostic Indicator for Patients with Renal Cell Carcinoma Undergoing Laparoscopic Nephrectomy: A Multi-Institutional Cohort Study. August 30, 2021

Outcomes in robotic-assisted partial nephrectomy for imperative versus elective indications. August 30, 2021

Aberration of lncRNA LINC00460 is a Promising Prognosis Factor and Associated with Progression of Clear Cell Renal Cell Carcinoma. August 27, 2021

Novel Volumetric and Morphological Parameters Derived from Three-dimensional Virtual Modeling to Improve Comprehension of Tumor's Anatomy in Patients with Renal Cancer. August 27, 2021

Impact of comorbidities on acute kidney injury and renal function impairment after partial and radical tumor nephrectomy. August 26, 2021

[Current treatment options for recurrent/metastatic renal cell carcinoma (mRCC)]. August 26, 2021

Lazarus 3D Announces First FDA Clearance for PREoperative SUrgical REhearsal (PRE-SURE®) Technology August 25, 2021

Infiltrative tumor interface with normal renal parenchyma in locally advanced renal cell carcinoma: Clinical relevance and pathological implications. August 25, 2021

Management of local recurrence after radical nephrectomy: surgical removal with or without systemic treatment is still the gold standard. Results from a multicenter international cohort. August 25, 2021

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma. August 24, 2021

Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. August 24, 2021

Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control Study. August 23, 2021

Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade. August 23, 2021

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. August 20, 2021

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG-ACRIN E2805 trial. August 20, 2021

Page 97 of 458